https://ansm.sante.fr/tableau-acces-derogatoire/balversa-erdafitinib 2025 false false false France French drug information erdafitinib administration, oral erdafitinib
--- https://www.ema.europa.eu/en/medicines/human/EPAR/balversa 2025 false false false Netherlands French English syndication feed summary of product characteristics package leaflet drug evaluation treatment outcome erdafitinib erdafitinib
--- https://www.has-sante.fr/jcms/p_3585759/fr/balversa-erdafitinib-carcinome-urothelial 2025 false false false France treatment outcome insurance, health, reimbursement erdafitinib Product containing only erdafitinib in oral dose form (medicinal product form) administration, oral FGFR Inhibitor receptors, fibroblast growth factor adult Unresectable Urothelial Carcinoma Metastatic Urothelial Carcinoma FGFR3 Gene Alteration Positive receptor, fibroblast growth factor, type 3 Alteration of genetic material (finding) evaluation of the transparency committee Balversa erdafitinib
--- https://www.has-sante.fr/jcms/p_3506762/fr/balversa-erdafitinib-carcinome-urothelial 2024 false false false France erdafitinib administration, oral Product containing only erdafitinib in oral dose form (medicinal product form) evaluation of the transparency committee erdafitinib erdafitinib Erdafitinib